tbuckley/cabot-search huggingface dataset:
Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis
Authors: M Navasa
Journal: Hepatology (1993)

Splanchnic and systemic hemodynamics and plasma levels of aldosterone, glucagon and plasma renin were investigated in 12 patients with advanced cirrhosis before and 2 wk (14.6 ± 2.8 days) and 2 mo (60.8 ± 10.5 days) after orthotopic liver transplantation. Liver transplant was followed by significant (p < 0.01) changes in systemic hemodynamics at 2 wk, with a marked reduction in cardiac index (4.9 ± 0.8 vs. 3.7 ± 0.7 L/min ± m2) and increases in mean arterial pressure (79 ± 8 vs. 101 ± 11 mm Hg) and peripheral vascular resistance (721 ± 149 vs. 1,274 ± 253 dyn ± sec ± cm−5). Two months after liver transplant, we saw further significant increases in peripheral vascular resistance (1,700 ± 341 dyn ± sec ± cm−5; p<0.05) without changes in cardiac index. Hepatic venous pressure gradient, very high before transplantation, was normal 2 wk after liver transplant (18.7 ± 3.0 vs. 2.1 ± 0.8 mm Hg; p < 0.01). Hepatic blood flow rose markedly from 1.03 ± 0.46 to 2.25 ± 0.79 L/min (p < 0.01) and was still elevated at 2 mo (1.84 ± 0.74 L/min). Azygos blood flow had not changed after 2 wk with respect to pretransplant values (0.65 ± 0.26 vs. 0.69 ± 0.39 L/min) but had decreased significantly at 2 mo (0.39 ± 0.16 L/min; p < 0.05). The elevated aldosterone, plasma renin and glucagon levels found in our cirrhotic patients before transplantation decreased to near-normal values 2 wk after the procedure. These results suggest that most of the hemodynamic and humoral abnormalities characteristic of advanced cirrhosis are reversed after liver transplant. However, azygos blood flow remains high early after liver transplant but is decreased at 2 mo, indicating that the closure of porto-collateral vessels occurs slowly despite the rapid normalization of portal pressure. The increase in hepatic blood flow after liver transplant may be a consequence of hepatic denervation. (HEPATOLOGY 1993;17:355–360.)
The 1987 US hospital AIDS survey
Authors: D. P. Andrulis
Journal: JAMA (1989)

In 1987, the National Public Health and Hospital Institute conducted a national survey of 623 acute-care hospitals to obtain information relating to inpatient and outpatient care for persons with acquired immunodeficiency syndrome (AIDS). Two hundred seventy-six hospitals reported treating persons with AIDS; the average length of stay was 16.8 days. Average costs and revenues per inpatient day were $681 and $545, respectively, with a cost per patient per year of $17 910. Estimated cost for AIDS inpatient care during 1987 was $486 million; Medicaid represented the primary payer. Regional and ownership comparisons for this year and between 1985 and 1987 indicated significant differences in utilization, payer source, and financing. Results suggest major differences in reimbursement and losses related to payer source or lack of insurance, with many hospitals that serve large numbers of low-income persons with AIDS encountering moderate to severe financial shortfalls. We conclude that increasing concentrations of persons with AIDS in relatively few hospitals in large cities may make it more difficult to secure the broader political base necessary to obtain adequate support for treatment. (<i>JAMA</i>. 1989;262:784-794)
Commitment to oncology.
Authors: K Halnan
Journal: BMJ (1977)

rate and thus afford equally as good results as for photon therapy in HPO or irradiation with fast neutrons.Such a trial might conflict with the individual preferences of radiotherapists but not with ethical considerations.Also it should be undertaken before less advanced, more curable cancers are submitted to trial by radiotherapeutic management by the techniques of HPO-photon or neutron therapy, whose advantages necessarily remain sub judice for lack of decisive information about optimal fractionation of dose "in air."
Donor Immunization with WT1 Peptide Augments Anti-Leukemic Activity After MHC-Matched Bone Marrow Transplantation
Authors: Holbrook E Kohrt, Antonia MS Mueller, Jeanette B Baker, Matthew J Goldstein, Evan Newell, Suparna Dutt, Debra K Czerwinski, Robert Lowsky, Samuel Strober
Journal: Blood (2011)
Candida Myocarditis Causing Complete Atrioventricular Block
Authors: John E. Van Kirk
Journal: JAMA (1974)

Complete heart block developed unexpectedly in a 54-year-old patient with acute myelomonocytic leukemia and was successfully treated with temporary transvenous pacing. Subsequent autopsy showed several microabscesses of<i>Candida albicans</i>in the His bundle, without evidence of leukemic infiltration or hemorrhage into the conduction system. While the general incidence and importance of<i>Candida</i>myocarditis in leukemic patients is unknown, fungal myocarditis with abscess formation should be considered as a cause of cardiac rhythm disturbances in these and other immunosuppressed patients.
Abstract 3793: Understanding the function of LMP1 CTAR3 in EBV-associated lymphomas
Authors: Tabithia Ross, Gretchen L. Bentz
Journal: Cancer Research (2019)

Abstract Background: Our present study aims to determine the function of the repetitive elements in the biology of Epstein-Barr virus (EBV) Latent Membrane Protein-1 (LMP1). Latent EBV infection is associated with distinct lymphoid and epithelial malignancies, and LMP1 is the principal oncoprotein of the virus. LMP1 has three C-terminal activating regions (CTARs) that induce multiple signal transduction pathways resulting in sustained cellular proliferation, increased cellular survival, and its oncogenic nature. CTAR1 and CTAR2 have been extensively characterized, but CTAR3 is much less studied. CTAR3 contains the LMP1 repetitive elements, which consist of 11-amino acid repeats and PxxPxP/Jak-interacting motifs. Analysis of over 200 clinical isolates revealed that there is significant variability in the number of 11-aaR (1.5-7.5 repeats) and PxxPxP-motives (1-2 repeats), but the exact function of these elements in oncogenesis is unknown. The findings of the study will greatly add to the understanding of the oncogenic nature of LMP1 and help to elucidate a specific purpose for the repetitive elements found within CTAR3. Methods: Using EBV B95.8 as our wild type strain, we constructed GFP-tagged LMP1 expression constructs that contain (1) wild type CTAR3; (2) PxxPxP only (no 11-aaR); (3) 11-aaR only (no PxxPxP); and (4) ΔCTAR3 (no 11-aaR or PxxPxP). These expression constructs were transfected into HEK 293 cells to assess the effect of the repeats on the trafficking and oncogenic potential of LMP1. Results: Findings suggest that the 11-aaR are necessary for correct intracellular and extracellular trafficking of LMP1. Loss of the 11-aaRs results in decreased plasma membrane-expressed LMP1 and the accumulation of LMP1 in intracellular membranes. Further, loss of the 11-aaR inhibits LMP1-induced cell migration, which suggests that the 11-aaR contribute to the oncogenic nature of LMP1. Conclusions: The number of 11-aaR found in LMP1 CTAR3 is variable in nature. Here we show that loss of the 11-aaR inhibits the normal biology of the oncoprotein, in that LMP1 trafficking is altered and the ability of the oncoprotein in promote cell migration is abrogated. Therefore, we propose that the CTAR3 11-aaR are essential to the oncogenic nature of LMP1. The role of these repeats during the transformation process and during tumorigenesis will be determined. Ultimately, further appreciation of the role of LMP1 CTAR3 in the biology of the virus may help identify potential targets for therapeutic interventions for EBV-associated malignancies. Citation Format: Tabithia Ross, Gretchen L. Bentz. Understanding the function of LMP1 CTAR3 in EBV-associated lymphomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3793.
Eugenical Sterilization. By<i>Abraham Myerson, M.D., James B. Ayer, M. D., Tracy J. Putnam, M. D., Clyde E. Keeler, Sc. D., Leo Alexander, M. D.</i>(New York: The Macmillan Co., 1936.)
Authors: C. B. F.
Journal: American Journal of Psychiatry (1937)
Tuberculosis Associated With Blocking Agents Against Tumor Necrosis Factor-Alpha—California, 2002-2003
Journal: JAMA (2004)

The Food and Drug Administration (FDA) has determined that tuberculosis (TB) disease is a potential adverse reaction from treatment with the tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab (Remicade), etanercept (Enbrel), and adalimumab (Humira); the three products are labeled accordingly. These products work by blocking TNF-alpha, an inflammatory cytokine, and are approved for treating rheumatoid arthritis and other selected autoimmune diseases. TNF-alpha is associated with the immunology and pathophysiology of certain infectious diseases, notably TB; blocking TNF-alphacan allow TB disease to emerge from latent Mycobacterium tuberculosis infection. In 2002, a California county health department reported three cases of TB disease occurring in association with infliximab therapy. This report summarizes those cases and nine subsequently reported cases and provides interim recommendations for TB prevention and management in recipients of these blocking agents. Health-care providers should take steps to prevent TB in immunocompromised patients and remain vigilant for TB as a cause of unexplained febrile illness.
Irradiation for inoperable carcinoma of the lung and high performance status
Authors: J. D. Cox
Journal: JAMA (1980)

Disagreement continues about the role of immediate irradiation of asymptomatic patients with inoperable lung cancer. Information pertaining specifically to irradiation of asymptomatic patients is scarce. The Medical College of Wisconsin, Milwaukee, reported that survival two years after irradiation was affected by control of the intrathoracic tumor. Ninety-two patients from that study with high performance status (80 to 100 on the Karnofsky scale) were evaluated for long-term survival. Of 54 patients (59%) whose tumors were controlled locally by irradiation, 22% survived five years. None of the 38 patients with uncontrolled thoracic disease lived beyond 27 months. Eight patients are alive and well 53 to 100 months after treatment. No specific late complications of irradiation have been seen. Patients having few symptoms with inoperable bronchial carcinoma can live many years if the tumor is controlled by irradiation. (<i>JAMA</i>244:1931-1933, 1980)
The Overdiagnosis of Lyme Disease
Authors: Joseph Burke
Journal: JAMA (1993)

<h3>To the Editor.</h3> —It is the year 1993 not 1983. Unfortunately, many physicians still do not realize that Lyme disease becomes chronic, if not treated early and aggressively. Steere et al<sup>1</sup>assert that the patients in the study did not have Lyme disease because these patients were still ill after 30 days of treatment. If these physicians used polymerase chain reaction or immune capture testing to eliminate the diagnosis of Lyme disease, it would have made their study credible; however, they had no objective data to give their claim merit. There is no evidence to prove that<i>Borrelia burgdorferi</i>can be eradicated in vivo in 30 days. Therefore, considering the fact that most chronically ill Lyme disease patients report continued improvement when antibiotic treatment is extended well beyond 30 days, Steere and his fellow researchers would have done a much greater service had they conducted a study on the
Low lipoprotein (a) levels during acute viral hepatitis
Authors: H Geiss
Journal: Hepatology (1996)

liver was supposed to be the major source of circulating Lp(a). High serum concentrations of lipoprotein (a) [Lp(a)]This finding was confirmed by the observation that after liver are considered a risk factor for premature atherosclerotransplantation the recipient acquired the donor's apo(a) phesis.Besides apolipoprotein B-100, Lp(a) consists of apolinotype. 12poprotein (a) [apo(a)], which shows a remarkable size According to recent studies, [13][14][15] not the total Lp(a) particle, polymorphism.The serum concentration of Lp(a) is conbut apo(a) is secreted by the hepatocyte.In a second step, it siderably influenced by this apo(a) phenotype.Because is extracellularly linked to apo B-100, possibly on the liver Lp(a) is synthesized in the liver, we wondered whether cell surface. 14and to what extent Lp(a) levels might be affected byIn chronic liver disease of different etiology, [16][17][18][19][20][21][22][23] a decreased acute liver disease.We compared Lp(a) serum concen-Lp(a) serum concentration has been found.However, the intrations in 74 patients (54% male, 46% female; mean age, fluence of acute liver damage on the Lp(a) concentration has 46 years) with acute viral hepatitis (32, 28, and 14 with not been studied systematically.The aim of our study was to hepatitis A, B, and C, respectively) with those in 404 investigate whether acute damage of the liver cell would also healthy controls (57% men, 43% women; mean age, 47 affect the Lp(a) serum concentration promptly.Therefore, we years).In addition, the intraindividual course of Lp(a)determined the Lp(a) serum concentrations in 74 patients concentration during and after acute hepatitis was folwith acute viral hepatitis compared with 404 healthy controls lowed in a subgroup of 23 patients (15, 6, and 2 with in a cross-sectional study.The apo(a) isoforms were deterhepatitis A, B, and C, respectively).During acute hepatimined in both groups to exclude any influence of an unequal tis, median Lp(a) concentrations in the patient group apo(a) isoform distribution.Furthermore, 23 patients were were significantly diminished compared with controls studied again after recovery from acute hepatitis (longitudi-(7 vs. 17 mg/dL; P õ .0001,Mann-Whitney test).Any bias nal study).by an unequal isoform distribution was excluded because there was no significant difference in the isoform distribution between patients and controls (P ú .10,x 2 Abbreviations: Lp(a), lipoprotein (a); apo(a), apolipoprotein (a); mRNA, messenger RNA;(SChE) levels, and prothrombin time were determined during the SChE, serum acylcholine acylhydrolase.presentation of patients according to clinical needs.
Plague and the peripheral smear
Authors: J. M. Mann
Journal: JAMA (1984)

The peripheral blood smear shown here was obtained from a fatal case of plague in a New Mexico resident. Plague was confirmed by isolation of<i>Yersinia pestis</i>from postmortem blood cultures. Plague is a zoonosis caused by the gram-negative coccobacillus<i>Y pestis</i>.<sup>1-4</sup>The disease is transmitted to humans either by flea vectors or, less commonly, by direct contact with plagueinfected animals, which can include dogs, cats, and other carnivores, in addition to the usual rodent and rabbit hosts of the disease. In addition, if a pneumonia secondary to hematogenous spread of<i>Y pestis</i>develops in patients with plague, person-to-person transmission of the disease becomes possible, thereby creating an urgent public health concern. After the introduction of rat plague to West Coast port cities in the late 19th and early 20th centuries, animal plague entered sylvatic rodent populations throughout the American West.<sup>2</sup>The first human plague reported in the
XVIII. NONSPECIFIC PROTEIN THERAPY IN ARTHRITIS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stroke: physical and financial pathology
Journal: BMJ (2002)

Chemoprevention agents must have low toxicities compared with chemotherapeutic agents used in cancer patients.In his clinical review, Greenwald (p 714) recommends that doctors should identify patients at high risk of cancer who might benefit from participation in chemoprevention trials.Validation of surrogate end point biomarkers is essential to reduce size and duration of chemoprevention trials.Greenwald also recommends that doctors emphasise cancer prevention in addition to cancer treatment and cure as it is a multistage disease, not a single event.
Letter: Immunisation against whooping cough.
Authors: G T Stewart
Journal: BMJ (1976)

lives and visits are often infrequent.To this extent, therefore, I see the community hospital in populations in excess of 40 000 being of primary significance to the community in respect of acute diagnostic and surgical services at an appropriate level, and the geriatric and long-stay element as a part of the overall picture rather than the pre- dominant feature.In populations less than this figure, however, then I would agree entirely with Dr Evans's comments about the role of community hospitals.This assumes that they can be viable in small communities, and this again is an area that, I would suggest, needs careful study in relation to the overall costs of these establishments set against the benefits to the community. KENNETH CLIFFWinchester Immunisation against whooping cough SIR,-In showing that 7500' of infants below 3 months of age with whooping cough were
Effect of radium-223 dichloride (Ra-223) on pain from US EAP.
Authors: Christopher Sweeney, A. Oliver Sartor, Nicholas J. Vogelzang, Neal D. Shore, Paul Cislo, Keith Bangerter, Michael J. Morris
Journal: Journal of Clinical Oncology (2015)

e16086 Background: Ra-223, a first-in-class alpha-emitting radiopharmaceutical, has shown pain palliation in phase 2 trials (Parker 2013; Nilsson 2012). Here we present the results of Ra-223 effect on pain from US EAP. Methods: Pain was assessed at baseline (BL), during treatment (trt), and follow-up (up to 6 mo after last trt visit) using the Brief Pain Inventory (BPI-SF) Questionnaire. The pain severity assessment was based on the worst pain item from the BPI-SF. The analysis was restricted to those not on opioids at BL due to incomplete data regarding mg of opioids received daily. Hypotheses tests were based on changes from baseline. A meaningful change in score was defined as ≥ 2 points from BL (Atkinson 2010). Results: Of 182 treated patients (pts) with BL pain scores, 109 were not on opioids at BL (6% had a score of 0 [no pain], 46% had 1-4 [mild pain], 34% had 5-7 [moderate pain], 14% had 8-10 [severe pain]). Among these 109 pts, 46/109 (42%) had improved pain (decrease of ≥ 2 points) without worsening, 20/109 (18%) had stable pain (no change of ≥ 2 points), 30/109 (28%) had worsening of pain (increase of ≥ 2 points or initiation of opioids) at some point and never had improvement, 11/109 (10%) had improvement and worsening at different times during trt, and 2/109 (2%) had no post-BL data (table presents data at each trt visit). Among the 109 pts, 107 pts had post-BL data. For the 107 pts, a significant decrease in mean pain severity from BL (P < 0.05) was observed at all trt visits. Among the 107 pts, 97 pts could have had pain improvement (BL score ≥ 2); 57 of the 97 pts (59%) experienced a reduction in pain during at least one on-trt visit. Conclusions: Radium-223 was associated with meaningful pain relief in 42% of pts, whereas 28% had worse pain and 18% no change. The confounding effect of change in opioids after initiation prevents adequate interpretation of this finding for pts on opioids at BL. Clinical trial information: NCT01516762. Pts Not on Opioids at Baseline, n/N (%) Improvement Worsening* Cycle 2 30/107 (28) 18/107 (17) Cycle 3 40/93 (43) 21/93 (23) Cycle 4 34/82 (41) 17/82 (21) Cycle 5 26/64 (41) 18/64 (28) Cycle 6 24/53 (45) 11/53 (21) Cycle 1 = baseline; N = patients with pain assessments at the trt visit. *Patients who initiated opioids during trt were censored as having worsening of pain at that trt visit.
Correction: Article on Th17 for IFNγ-Mediated Papilloma Promotion
Journal: Cancer Research (2009)

In the article on Th17 for IFNγ-mediated papilloma promotion in the March 1, 2009 issue of Cancer Research (1), the Acknowledgments section should have included the following:We sincerely express our gratitude to Professor Thomas Blankenstein for his help on this article. Some of the experiments reported in the article (Fig. 2D) were performed at the Institute of Immunology, Charite Universitätsmedizin Berlin, Berlin, Germany under the supervision of Prof. Blankenstein. Experiments described in Fig. 2D were supported by the Deutsche Forschungsgemeinschaft by a grant to Prof. Blankenstein as Principal Investigator and Z. Qin as Co-Investigator (BL288-1).The authors apologize for having omitted this fact.
Radiocarbon Dating
Authors: W. F. LIBBY
Journal: Annals of Internal Medicine (1963)

Special Article1 October 1963Radiocarbon DatingW. F. LIBBY, PH.D.W. F. LIBBY, PH.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-59-4-566 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptRadiocarbon dating had its origin in a study of the possible effects that cosmic rays might have on the earth and on the earth's atmosphere. We were interested in testing whether any of the various effects which might be predicted could actually be found and used. Initially, the problem seemed rather difficult, for ignorance of billion-electron volt nuclear physics (cosmic ray energies are in this range) was so abysmal at the time (and incidentally, 15 years later is still abysmal) that it is nearly impossible to predict with any certainty the effects of the collisions of the multibillion-volt primary cosmic...References1. LIBBY WF: Radiocarbon Dating, 2nd ed., University of Chicago Press, Chicago, Illinois, 1955. Google Scholar2. ANONYMOUS: Accuracy of radiocarbon dates. Science 140: 278, 1963. CrossrefMedlineGoogle Scholar3. FLINTDEEVEY RFES editors: American Journal of Science Radiocarbon Supplement I: 1959, II: 1960, III: 1961, IV: 1962. Google Scholar4. GODWIN H: Radiocarbon dating, Fifth International Conference. Nature 195: 943, 1962. CrossrefGoogle Scholar5. ANONYMOUS: Half-life of radiocarbon. Nature 195: 984, 1962. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Los Angeles, CaliforniaFrom the Department of Chemistry, University of California, Los Angeles, California.Research was supported generously by the Viking Fund of New York City (now the Axel Wenner-Gren Foundation), The United Slates Air Force, the Geological Society, the Guggenheim Foundation, and by the University of Chicago where most of the research was done.Presented as a lecture before the Convocation of the American College of Physicians, Denver, Colorado, April 4, 1963.Requests for reprints should be addressed to Professor W. F. Libby, Department of Chemistry, University of California, Los Angeles 24, California. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1963Volume 59, Issue 4Page: 566-579 Issue Published: 1 October 1963 PDF DownloadLoading ...